American Journal of Hematology
Nov 10, 2025, 10:37
Should Transferrin Saturation Guide HFE-Hemochromatosis Therapy?
American Journal of Hematology shared on X:
“In HFE-hemochromatosis, transferrin saturation above ~75% suggests harmful non-transferrin-bound iron levels. Due to assay limits for NTBI, monitoring TSAT levels during maintenance therapy may help and should guide care until accurate NTBI tests exist.”
Title: Should Serum Transferrin Saturation Be Included as a Therapeutic Target in Addition to Serum Ferritin in Treating HFE-Hemochromatosis?
Authors: Nils Thorm Milman, Christina Ellervik
Read the full article here.
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia